tetano
Editor, Senior Moderator
Cell Rep Med
. 2023 Feb 7;100955.
doi: 10.1016/j.xcrm.2023.100955. Online ahead of print.
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4[SUP]+[/SUP] T cell profile
Gérémy Sannier[SUP] 1 [/SUP], Alexandre Nicolas[SUP] 1 [/SUP], Mathieu Dubé[SUP] 2 [/SUP], Lorie Marchitto[SUP] 1 [/SUP], Manon Nayrac[SUP] 1 [/SUP], Olivier Tastet[SUP] 2 [/SUP], Debashree Chatterjee[SUP] 1 [/SUP], Alexandra Tauzin[SUP] 1 [/SUP], Raphaël Lima-Barbosa[SUP] 3 [/SUP], Mélanie Laporte[SUP] 2 [/SUP], Rose Cloutier[SUP] 2 [/SUP], Alina M Sreng Flores[SUP] 2 [/SUP], Marianne Boutin[SUP] 1 [/SUP], Shang Yu Gong[SUP] 4 [/SUP], Mehdi Benlarbi[SUP] 1 [/SUP], Shilei Ding[SUP] 2 [/SUP], Catherine Bourassa[SUP] 2 [/SUP], Gabrielle Gendron-Lepage[SUP] 2 [/SUP], Halima Medjahed[SUP] 2 [/SUP], Guillaume Goyette[SUP] 2 [/SUP], Nathalie Brassard[SUP] 2 [/SUP], Gloria-Gabrielle Delgado[SUP] 2 [/SUP], Julia Niessl[SUP] 1 [/SUP], Laurie Gokool[SUP] 2 [/SUP], Chantal Morrisseau[SUP] 2 [/SUP], Pascale Arlotto[SUP] 2 [/SUP], Norka Rios[SUP] 5 [/SUP], Cécile Tremblay[SUP] 1 [/SUP], Valérie Martel-Laferrière[SUP] 1 [/SUP], Alexandre Prat[SUP] 6 [/SUP], Justin Bélair[SUP] 3 [/SUP], William Beaubien-Souligny[SUP] 7 [/SUP], Rémi Goupil[SUP] 8 [/SUP], Annie-Claire Nadeau-Fredette[SUP] 9 [/SUP], Caroline Lamarche[SUP] 9 [/SUP], Andrés Finzi[SUP] 10 [/SUP], Rita S Suri[SUP] 11 [/SUP], Daniel E Kaufmann[SUP] 12 [/SUP]
Affiliations
Abstract
Cellular immune defects associated with suboptimal responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination in people receiving hemodialysis (HD) are poorly understood. We longitudinally analyze antibody, B cell, CD4[SUP]+[/SUP], and CD8[SUP]+[/SUP] T cell vaccine responses in 27 HD patients and 26 low-risk control individuals (CIs). The first two doses elicit weaker B cell and CD8[SUP]+[/SUP] T cell responses in HD than in CI, while CD4[SUP]+[/SUP] T cell responses are quantitatively similar. In HD, a third dose robustly boosts B cell responses, leads to convergent CD8[SUP]+[/SUP] T cell responses, and enhances comparatively more T helper (T[SUB]H[/SUB]) immunity. Unsupervised clustering of single-cell features reveals phenotypic and functional shifts over time and between cohorts. The third dose attenuates some features of T[SUB]H[/SUB] cells in HD (tumor necrosis factor alpha [TNFα]/interleukin [IL]-2 skewing), while others (CCR6, CXCR6, programmed cell death protein 1 [PD-1], and HLA-DR overexpression) persist. Therefore, a third vaccine dose is critical to achieving robust multifaceted immunity in hemodialysis patients, although some distinct T[SUB]H[/SUB] characteristics endure.
Keywords: B cell immunity; COVID-19; Hemodialysis; Immune cell phenotyping; SARS-CoV-2; T cell immunity; Vaccine response; mRNA vaccine.
. 2023 Feb 7;100955.
doi: 10.1016/j.xcrm.2023.100955. Online ahead of print.
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4[SUP]+[/SUP] T cell profile
Gérémy Sannier[SUP] 1 [/SUP], Alexandre Nicolas[SUP] 1 [/SUP], Mathieu Dubé[SUP] 2 [/SUP], Lorie Marchitto[SUP] 1 [/SUP], Manon Nayrac[SUP] 1 [/SUP], Olivier Tastet[SUP] 2 [/SUP], Debashree Chatterjee[SUP] 1 [/SUP], Alexandra Tauzin[SUP] 1 [/SUP], Raphaël Lima-Barbosa[SUP] 3 [/SUP], Mélanie Laporte[SUP] 2 [/SUP], Rose Cloutier[SUP] 2 [/SUP], Alina M Sreng Flores[SUP] 2 [/SUP], Marianne Boutin[SUP] 1 [/SUP], Shang Yu Gong[SUP] 4 [/SUP], Mehdi Benlarbi[SUP] 1 [/SUP], Shilei Ding[SUP] 2 [/SUP], Catherine Bourassa[SUP] 2 [/SUP], Gabrielle Gendron-Lepage[SUP] 2 [/SUP], Halima Medjahed[SUP] 2 [/SUP], Guillaume Goyette[SUP] 2 [/SUP], Nathalie Brassard[SUP] 2 [/SUP], Gloria-Gabrielle Delgado[SUP] 2 [/SUP], Julia Niessl[SUP] 1 [/SUP], Laurie Gokool[SUP] 2 [/SUP], Chantal Morrisseau[SUP] 2 [/SUP], Pascale Arlotto[SUP] 2 [/SUP], Norka Rios[SUP] 5 [/SUP], Cécile Tremblay[SUP] 1 [/SUP], Valérie Martel-Laferrière[SUP] 1 [/SUP], Alexandre Prat[SUP] 6 [/SUP], Justin Bélair[SUP] 3 [/SUP], William Beaubien-Souligny[SUP] 7 [/SUP], Rémi Goupil[SUP] 8 [/SUP], Annie-Claire Nadeau-Fredette[SUP] 9 [/SUP], Caroline Lamarche[SUP] 9 [/SUP], Andrés Finzi[SUP] 10 [/SUP], Rita S Suri[SUP] 11 [/SUP], Daniel E Kaufmann[SUP] 12 [/SUP]
Affiliations
- PMID: 36863335
- DOI: 10.1016/j.xcrm.2023.100955
Abstract
Cellular immune defects associated with suboptimal responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination in people receiving hemodialysis (HD) are poorly understood. We longitudinally analyze antibody, B cell, CD4[SUP]+[/SUP], and CD8[SUP]+[/SUP] T cell vaccine responses in 27 HD patients and 26 low-risk control individuals (CIs). The first two doses elicit weaker B cell and CD8[SUP]+[/SUP] T cell responses in HD than in CI, while CD4[SUP]+[/SUP] T cell responses are quantitatively similar. In HD, a third dose robustly boosts B cell responses, leads to convergent CD8[SUP]+[/SUP] T cell responses, and enhances comparatively more T helper (T[SUB]H[/SUB]) immunity. Unsupervised clustering of single-cell features reveals phenotypic and functional shifts over time and between cohorts. The third dose attenuates some features of T[SUB]H[/SUB] cells in HD (tumor necrosis factor alpha [TNFα]/interleukin [IL]-2 skewing), while others (CCR6, CXCR6, programmed cell death protein 1 [PD-1], and HLA-DR overexpression) persist. Therefore, a third vaccine dose is critical to achieving robust multifaceted immunity in hemodialysis patients, although some distinct T[SUB]H[/SUB] characteristics endure.
Keywords: B cell immunity; COVID-19; Hemodialysis; Immune cell phenotyping; SARS-CoV-2; T cell immunity; Vaccine response; mRNA vaccine.